Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
Launched by JIMMA UNIVERSITY · Feb 1, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called bromocriptine on women with dilated cardiomyopathy (DCM), a serious heart condition that affects how well the heart pumps blood. DCM can lead to heart failure and is particularly concerning for younger women, especially during and after pregnancy. Researchers want to see if bromocriptine can improve heart function, relieve heart failure symptoms, and enhance the quality of life for these women. The trial is open to women aged 18 to 50 who have either newly diagnosed or existing DCM, but it excludes those with certain other heart conditions or severe health issues.
If you participate in this study, you will receive bromocriptine for monitoring and evaluation. Throughout the trial, you will be closely observed to check how well your heart is functioning and whether your symptoms improve. It’s important to note that this study is specifically focused on women of reproductive age, as hormonal factors may influence the condition. If you think you might be eligible and are interested in participating, this could be an opportunity to contribute to research that may benefit many women with DCM.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women age 18 years to 50 years and
- • ischemic or de novo dilated cardiomyopathy
- Exclusion Criteria:
- • Patients with severe comorbidities which may worsen their illness
- • with hypertensive heart diseases
- • Rheumatic valvular heart diseases
- • Restrictive cardiomyopathy, constrictive cardiomyopathy, hypertrophic cardiomyopathy
- • Congenital heart diseases
- • Acute coronary syndrome
- • Overt kidney failure (serum Creatinine ≥ 1.4mg/dl),
- • Women who had history of peripartal cardiomyopathy, are pregnant or planning pregnancy during the study period or lactating
- • Previous adverse reaction to the bromocriptine
- • Patients not willing to participate in the study
About Jimma University
Jimma University is a leading academic institution in Ethiopia, renowned for its commitment to advancing health sciences and promoting research initiatives. As a clinical trial sponsor, Jimma University leverages its extensive expertise in public health and medicine to conduct rigorous and ethical research aimed at addressing critical health challenges in the region. The university collaborates with various stakeholders, including local and international research organizations, to enhance the quality and impact of its clinical studies. By fostering innovation and knowledge dissemination, Jimma University plays a pivotal role in improving health outcomes and contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jimma, Oromia, Ethiopia
Patients applied
Trial Officials
Kedir N Tukeni, MD
Principal Investigator
Jimma University
Haas A Nikolaus, MD, Cardiologist
Study Chair
Ludwig Maximillian university of Munich
Estner F Heidi, MD, cardiologist
Study Chair
Ludwig Maximillian university of Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported